Stonepine Capital Management’s Amryt Pharma plc American Depositary Shares AMYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-6,278,085
Closed -$91.5M 25
2023
Q1
$91.5M Sell
6,278,085
-55,154
-0.9% -$779K 30.7% 1
2022
Q4
$46.2M Buy
6,333,239
+105,506
+2% +$744K 19.45% 1
2022
Q3
$43.1M Sell
6,227,733
-70,615
-1% -$527K 19.37% 1
2022
Q2
$44M Sell
6,298,348
-39,852
-0.6% -$311K 20.48% 1
2022
Q1
$52.4M Buy
6,338,200
+268,425
+4% +$2.42M 21.74% 1
2021
Q4
$65.6M Buy
6,069,775
+268,027
+5% +$2.89M 30.08% 1
2021
Q3
$69.9M Buy
5,801,748
+3,004,004
+107% +$33.9M 31.8% 1
2021
Q2
$33.9M Buy
2,797,744
+274,016
+11% +$3.4M 17.75% 1
2021
Q1
$35.2M Buy
2,523,728
+1,107,245
+78% +$15.5M 18.99% 1
2020
Q4
$20.1M Buy
1,416,483
+651,247
+85% +$8.5M 15.35% 2
2020
Q3
$9.46M Buy
+765,236
New +$8.86M 9.84% 3

Stonepine Capital Management's AMYT Position: Q2 2023 in Review

Stonepine Capital Management sold out of Amryt Pharma plc American Depositary Shares (AMYT) in Q2 2023, closing a stake of 6,278,085 shares — an estimated $91.5M sold.

Stonepine Capital Management first reported a position in AMYT in Q3 2020 and held it in 11 quarters. The position peaked at $91.5M in Q1 2023. 0 funds tracked by Wall St. Rank hold AMYT as of Q2 2023.

  • Stonepine Capital Management reported no remaining Amryt Pharma plc American Depositary Shares position as of Q2 2023 after selling out during the quarter.
  • Stonepine Capital Management sold 6,278,085 Amryt Pharma plc American Depositary Shares shares in Q2 2023, an estimated $91.5M.
  • Stonepine Capital Management first reported a position in Amryt Pharma plc American Depositary Shares in Q3 2020 and held it in 11 quarters.
  • Stonepine Capital Management's Amryt Pharma plc American Depositary Shares position peaked at $91.5M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Amryt Pharma plc American Depositary Shares as of Q2 2023.

Based on Stonepine Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.